Trial Profile

A randomized, double-blind clinical trial of Setmelanotide in patients with Bardet-Biedl-Syndrome (BBS)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 03 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Setmelanotide (Primary)
Indications Bardet-Biedl Syndrome
Focus Therapeutic Use
Acronyms de novo

Most Recent Events

01 Aug 2023 According to a Rhythm media release, company announced this trial will initiate in 2024.
08 Nov 2022 According to a Rhythm media release, this study of setmelanotide in patients with BBS will be initiated in the first half of 2023.
12 Jul 2022 According to a Rhythm media release, the company look forward to engaging with regulatory agencies to finalize our Phase 3 development plans in the months ahead.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com